T1	PrimaryOutcome 48 86	reduction in lethality by at least 50%
T2	TimeFrame 234 243	on day 13
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	SecondaryOutcome 275 302	participant clinical status
T4	SecondaryOutcome 304 327	laboratory examinations
T6	TimeFrame 387 396	to day 28
R2	MeasuredAt Arg1:T3 Arg2:T6	
R3	MeasuredAt Arg1:T4 Arg2:T6	
T7	OtherOutcome 398 439	Viral respiratory secretion RNA detection
T8	TimeFrame 454 469	on days 0 and 4
R5	MeasuredAt Arg1:T7 Arg2:T8	
T9	OtherOutcome 508 553	adverse events that occurred during treatment
T10	OtherOutcome 555 577	serious adverse events
T11	OtherOutcome 583 634	premature or temporary discontinuation of treatment
T12	OutcomeDefinition 656 756	classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events
R6	DefinedAs Arg1:T9 Arg2:T12	
T5	SecondaryOutcome 1060 1077	electrocardiogram
T13	TimeFrame 1078 1095	on days 13 and 28
R4	MeasuredAt Arg1:T5 Arg2:T13	
T14	SecondaryOutcome 1097 1141	daily clinical status during hospitalization
T15	SecondaryOutcome 1143 1193	duration of mechanical ventilation (if applicable)
T16	SecondaryOutcome 1198 1234	supplementary oxygen (if applicable)
T17	SecondaryOutcome 1244 1293	time (in days) from treatment initiation to death
T18	SecondaryOutcome 985 994	lethality
T19	SecondaryOutcome 1006 1033	participant clinical status
T20	SecondaryOutcome 1035 1058	laboratory examinations
T21	TimeFrame 995 1004	on day 13
R7	MeasuredAt Arg1:T18 Arg2:T21	
